Alzamend Neuro, Inc.
ALZN$8M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaATLANTA
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
ALZN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
AL001
Alzheimer's Disease
ALZN002 (autologous DCs pulsed with E22W mutant peptide).
Alzheimer Disease
Lithium carbonate
Bipolar I Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL001 | Phase 2 | Alzheimer's Disease | - | - |
ALZN002 (autologous DCs pulsed with E22W mutant peptide). | Phase 2 | Alzheimer Disease | - | - |
Lithium carbonate | Phase 2 | Bipolar I Disorder | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply